MedPath

Effect of RIC on Cerebral Autoregulation in Patients Undergoing Cerebrovascular Stent Implantation

Not Applicable
Recruiting
Conditions
Remote Ischemic Conditioning
Interventions
Procedure: Remote ischemic conditioning
Procedure: Sham remote ischemic conditioning
Registration Number
NCT05970653
Lead Sponsor
Yi Yang
Brief Summary

The purpose of this study is to determine the effect of remote ischemic conditioning on cerebral autoregulation in patients undergoing cerebrovascular stent implantation.

Detailed Description

In this study, 104 cases of patients with cerebrovascular stent implantation will be enrolled in the First Hospital of Jilin University, and they will be divided into the RIC group and the sham-RIC group. The RIC group received remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days or from enrollment to discharge. The sham-RIC group received remote ischemic conditioning for 60mmHg, 2 times per day for 7 consecutive days or from enrollment to discharge. Two groups will be followed up to evaluate the effect of remote ischemic conditioning on cerebral autoregulation in patients undergoing cerebrovascular stent implantation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
104
Inclusion Criteria
  • Age≥18 years, regardless of sex;
  • Patients with symptomatic or asymptomatic cerebral vascular stenosis (including internal carotid artery system and vertebrobasilar system) who are candidates for elective cerebrovascular stenting.
  • Patients or their immediate family members are able and willing to sign informed consent.
Exclusion Criteria
  • Patients with progressive stroke;
  • mRS≥ 2 points before admission;
  • Patients with other surgical treatments;
  • Patients with other serious diseases or a life expectancy of less than 3 months
  • Patients who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper extremities, venous thrombosis in the acute or subacute stage of upper extremities;
  • Laboratory test indicators are unqualified: aspartate aminotransferase or alanine aminotransferase is 3 times higher than the upper limit of the normal range, blood creatinine > 265umol/L (>3mg/dl), platelet < 100×109/L, international normalized ratio (INR), activated partial thromboplastin time (APTT), prothrombin time (PT) exceed the upper limit of the normal range;
  • Pregnant or lactating women;
  • Patients who are participating in other clinical studies, or who have participated in other clinical studies within 3 months prior to enrollment;
  • Unwillingness to be followed up or poor adherence to treatment;
  • Other circumstances that the investigator considers unsuitable for enrolment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RIC GroupRemote ischemic conditioningRemote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
Sham-RIC GroupSham remote ischemic conditioningRemote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days or from enrollment to discharge.
Primary Outcome Measures
NameTimeMethod
Cerebral autoregulation parameter0-7 days

Cerebral autoregulation parameters derived from transfer function analysis. Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler. Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size. Transfer function analysis will be used to derive the autoregulatory parameter.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

First Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

© Copyright 2025. All Rights Reserved by MedPath